致耐受性树突状细胞和调节性T细胞在支气管哮喘中的作用  

Role of tolerogenic dendritic cells and regulatory T cells in bronchial asthma

作　　者：汪凤凤[1] 苗伟伟[1] 刘洪泱[1] 周林福[1] 

机构地区：[1]南京医科大学第一附属医院呼吸内科,210029

出　　处：《中华哮喘杂志（电子版）》2013年第1期44-48,共5页Chinese Journal of Asthma(Electronic Version)

基　　金：国家自然科学基金(81170018);江苏省医学重点人才项目(RC2011066);江苏省333高层次人才培养工程(201115);江苏省高校自然科学研究项目(11KJB320008);江苏省高校优势学科建设工程(JX10231801);江苏省卫生国际交流支撑计划(201235)

摘　　要：支气管哮喘是树突状细胞(dendritic cells,DC)介导的以辅助性T细胞2(T-helper type2,Th2)优势免疫为特征的气道炎症性疾病,DC在变应原触发哮喘的始动环节中发挥中心作用。调节性T细胞(regulatory T cells,Treg)是一种特殊的T细胞,能够通过多种机制影响DC和效应性T细胞,从而发挥免疫抑制作用。DC不仅对入侵病原体产生免疫应答,而且对无害物质维持免疫耐受。这些具有致耐受性的DC通过多种不同的路径诱导Treg,上调Treg数目和(或)功能,从而抑制免疫应答。应用致耐受性DC作为靶点,有望为哮喘免疫治疗开辟新的途径。Bronchial asthma (asthma) is a dendritic cells (DC)-mediated,T-helper type 2 (Th2) immunity-biased airway inflammatory disorder. DC play a central role in the allergen trigger asthma.The regulatory T cells (Treg) are specialized T cells that exert their immuno-suppressive function through a variety of mechanisms affecting both DC and effector cells. DC not only produce immune response to the pathogen of invasion, but also maintain immune tolerance to innocuous substances. These tolerogenic DC upregulate the number and (or) function of Treg trough multiple pathways that may act either alone or in combination,leading to inhibition of the immune response. It is promising for immunotherapy of asthma by targeting the tolerogenic DC.

关 键 词：致耐受性树突状细胞 调节性T细胞 免疫治疗 支气管哮喘 

分 类 号：R5[医药卫生—内科学] R9[医药卫生—临床医学]